• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al.

作者信息

Kamburova Elena G, Koenen Hans J M P, Joosten Irma, Hilbrands Luuk B

出版信息

Arthritis Rheum. 2013 Apr;65(4):1130-1. doi: 10.1002/art.37871.

DOI:10.1002/art.37871
PMID:23335076
Abstract
摘要

相似文献

1
CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al.利妥昔单抗治疗后，CD19是一种有用的B细胞标志物：对琼斯等人文章的评论
Arthritis Rheum. 2013 Apr;65(4):1130-1. doi: 10.1002/art.37871.
2
B cells identified according to their expression of CD19 and surface Ig are depleted from peripheral blood by rituximab in patients with rheumatoid arthritis: comment on the article by Jones et al.在类风湿关节炎患者中，根据CD19表达和表面免疫球蛋白鉴定出的B细胞会被利妥昔单抗从外周血中清除：对Jones等人文章的评论
Arthritis Rheum. 2013 Apr;65(4):1132. doi: 10.1002/art.37869.
3
Reply: To PMID 22674374.回复：针对 PMID 22674374。
Arthritis Rheum. 2013 Apr;65(4):1132-3. doi: 10.1002/art.37870.
4
Rituximab mediates loss of CD19 on B cells in the absence of cell death.利妥昔单抗在不引起细胞死亡的情况下介导B细胞上CD19的丧失。
Arthritis Rheum. 2012 Oct;64(10):3111-8. doi: 10.1002/art.34560.
5
CD22 is not expressed merely on B cells: comment on the article by Vos et al.CD22并非仅在B细胞上表达：对Vos等人文章的评论
Arthritis Rheum. 2008 Mar;58(3):911-2; author reply 912-3. doi: 10.1002/art.23282.
6
Re-treatment of rheumatoid arthritis patients who were initial nonresponders to rituximab: comment on the article by Thurlings et al.
Arthritis Rheum. 2009 Jun;60(6):1867; author reply 1867-8. doi: 10.1002/art.24558.
7
CD19 mRNA quantification improves rituximab treatment-to-target approach: a proof of concept study.CD19信使核糖核酸定量改善利妥昔单抗治疗达标方法：一项概念验证研究
J Neuroimmunol. 2014 Dec 15;277(1-2):127-33. doi: 10.1016/j.jneuroim.2014.09.008. Epub 2014 Sep 20.
8
Efficacy of rituximab in a patient with lupus nephritis despite low levels of CD19.
Rheumatology (Oxford). 2010 Dec;49(12):2452-3. doi: 10.1093/rheumatology/keq186. Epub 2010 Jun 29.
9
Successful treatment and clearing of circulating CD19-positive cells by rituximab in a child with idiopathic membranous nephropathy.利妥昔单抗成功治疗并清除一名特发性膜性肾病患儿循环中的CD19阳性细胞。
Pediatr Nephrol. 2011 Apr;26(4):637-8. doi: 10.1007/s00467-010-1671-2. Epub 2010 Oct 29.
10
CD20 epitope masking by rituximab: comment on the article by Gunnarsson et al.利妥昔单抗对CD20表位的掩盖：对贡纳松等人文章的评论
Arthritis Rheum. 2008 Feb;58(2):634; author reply 634. doi: 10.1002/art.23298.

引用本文的文献

1
Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.补体依赖性 CD20 特异性 IgG 活性与二价抗原结合和 C1q 结合强度相关。
Front Immunol. 2021 Jan 11;11:609941. doi: 10.3389/fimmu.2020.609941. eCollection 2020.
2
Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.利妥昔单抗治疗儿童起病、难治性肾病综合征的疗效与安全性：韩国一项多中心开放标签试验
Medicine (Baltimore). 2018 Nov;97(46):e13157. doi: 10.1097/MD.0000000000013157.
3
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
CD19 抗体 MOR208 治疗复发或难治性 B 细胞非霍奇金淋巴瘤的 IIa 期研究。
Ann Oncol. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056.
4
Extra-central nervous system target for assessment and treatment in refractory anti-N-methyl-d-aspartate receptor encephalitis.难治性抗N-甲基-D-天冬氨酸受体脑炎的中枢神经系统外评估与治疗靶点
J Crit Care. 2017 Feb;37:234-236. doi: 10.1016/j.jcrc.2016.09.016. Epub 2016 Sep 22.
5
Refractory Autoimmune Hepatitis: Beyond Standard Therapy.难治性自身免疫性肝炎：超越标准治疗
Dig Dis Sci. 2016 Jun;61(6):1757-62. doi: 10.1007/s10620-015-4022-0. Epub 2016 Jan 2.